Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Correlation of response with overall survival (OS) for nivolumab vs everolimus in advanced renal cell carcinoma (aRCC): Results from the phase III CheckMate 025 study
Correlation of response with overall survival (OS) for nivolumab vs everolimus in advanced renal cell carcinoma (aRCC): Results from the phase III CheckMate 025 study Motzer, R. J., Sharma, P., Escudier, B. J., McDermott, D. F., George, S., Srinivas, S., Tykodi, S. S., Sosman, J., Plimack, E. R., Nathan, P. D., Gruenwald, V., Tomita, Y., Zhao, H., Waxman, I. M., Hammers, H. J. AMER SOC CLINICAL ONCOLOGY. 2016View details for DOI 10.1200/JCO.2016.34.15_suppl.4552
View details for Web of Science ID 000404665407125